Table of Contents:
Individual chapters are available for $25 each by sending an email to firstname.lastname@example.org. Nova will provide the chapter for your easy downloading or send it as an email attachment if you prefer.
Preface; Chapter 1. DNA and its Relationship to Cancer (Spyros Vlachopoulos and Vassilis Zoumpourlis, Institute of Biological Research and Biotechnology, Greece); Chapter 2. Global Amplification of Sense RNA: A Novel Method to Replicate and Archive RNA for Cancer Biomarker Discovery and Validation (Mangalathu S. Rajeevan et al., National Center for Infectious Diseases, Centers for Disease Control and Prevention); Chapter 3. Genome Reviews and Proteome Analysis (Nadeem Faruque et al., European Bioinformatics Institute); Chapter 4. Genomics and Proteomics in the Early Detection and Prevention of Cancer (Fiona Simpkins et al., National Cancer Institute, Bethesda); Chapter 5. Proteomic Analyses in Oncology (Alasdair C Stamps et al., Celltech R&D, England); Chapter 6. SELDI-TOF Profiling for Clinical Diagnostic Assay Development (Lisa H. Cazares et al., Eastern Virginia Medical School); Chapter 7. Proteomic Techniques for Individualized Cancer Therapy (Lorri-Anne F. Burke et al., National Cancer Institute, Bethesda); Chapter 8. Proteomics in Breast Cancer (Serhiy Souchelnytskyi, Ludwig Institute for Cancer Research, Sweden); Chapter 9. Application of Proteomics to Prostate Cancer Research (Hidetoshi Kuruma et al., Kitasato University School of Medicine, Japan); Chapter 10. The Role of Proteomics Applications in Brain Tumor Biomarker Discovery (A. Umar and T. M. Luider); Chapter 11. Tumor-associated Proteins in Chemically Induced Rat Hepatomas and their Analogous Proteins in Human Hepatocellular Carcinomas (Evelyn Zeindl-Eberhart et al., Institute of Pathology, University of Munich, Germany); Chapter 12. Gene Expression Profiling and its Application for Characterization of Mechanism(s) of Action of Anti-cancer Drugs, Molecular Classification and Prognostication in Hematologic Malignancies: Focus on Plasma Cell Dyscrasias (Constantine S. Mitsiades and Nicholas Mitsiades, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School); Chapter 13. Proteomic Profiling Studies for Delineation of Mechanism(s) of Action of Anti-cancer Drugs, Molecular Classification and Prognostication of Human Malignancies: Focus on Multiple Myeloma and other Plasma Cell Dyscrasias (Constantine S. Mitsiades and Nicholas Mitsiades, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School); Chapter 14. Biomarkers in Cancer Detection and Risk Assesment (Mukesh Verma and Sudhir Srivastava, National Cancer Institute, Bethesda); Chapter 15. Gene Expression Profile of Childhood Acute Lymphoblastic Leukemia During Chemotherapy by cDNA Microarrays (George I. Lambrou et al., University of Athens); Chapter 16. Epstein-Barr virus Infection and Viral Gene Expression in Pediatric Non-Hodgkin Lymphomas (Matthias A. Karajannis et al., Memorial Sloan-Kettering Cancer Center); Chapter 17. Genome and Proteome in Neuroblastoma (Kalliopi Gana et al., University of Athens); Index.